Literature DB >> 29038205

The Ethics of Conducting Clinical Trials With Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Is Placebo Assignment Justified in Patients With Comorbid Diabetes Mellitus and Heart Failure?

Javed Butler1, Stefan D Anker2.   

Abstract

Entities:  

Keywords:  SGLT2 inhibitor; empagliflozin; heart failure

Mesh：

Substances：

Year:  2017        PMID： 29038205     DOI： 10.1161/CIRCULATIONAHA.117.029284

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  6 in total

Review 1.  Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes.

Authors:  Stephen J Greene; Muthiah Vaduganathan; Muhammad Shahzeb Khan; George L Bakris; Matthew R Weir; Jonathan H Seltzer; Naveed Sattar; Darren K McGuire; James L Januzzi; Norman Stockbridge; Javed Butler
Journal:  J Am Coll Cardiol       Date:  2018-03-10       Impact factor: 24.094

Review 2.  Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes.

Authors:  Eberhard Standl; Oliver Schnell; Darren K McGuire
Journal:  Circ Res       Date:  2016-05-27       Impact factor: 17.367

3.  Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics.

Authors:  Salvatore Carbone; Justin M Canada; Hayley E Billingsley; Dinesh Kadariya; Dave L Dixon; Cory R Trankle; Leo F Buckley; Roshanak Markley; Chau Vo; Horacio Medina de Chazal; Sanah Christopher; Raffaella Buzzetti; Benjamin W Van Tassell; Antonio Abbate
Journal:  Diabetes Obes Metab       Date:  2018-04-23       Impact factor: 6.577

4.  Empagliflozin, calcium, and SGLT1/2 receptor affinity: another piece of the puzzle.

Authors:  Stefan D Anker; Javed Butler
Journal:  ESC Heart Fail       Date:  2018-07-19

5.  Empagliflozin prevents neointima formation by impairing smooth muscle cell proliferation and accelerating endothelial regeneration.

Authors:  Jochen Dutzmann; Lena Marie Bode; Katrin Kalies; Laura Korte; Kai Knöpp; Frederik Julius Kloss; Mirja Sirisko; Claudia Pilowski; Susanne Koch; Heiko Schenk; Jan-Marcus Daniel; Johann Bauersachs; Daniel G Sedding
Journal:  Front Cardiovasc Med       Date:  2022-08-09

6.  Totality of evidence in trials of sodium-glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice.

Authors:  Javed Butler; Faiez Zannad; Gerasimos Filippatos; Stefan D Anker; Milton Packer
Journal:  Eur Heart J       Date:  2020-09-21       Impact factor: 29.983
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.